CO6680653A2 - Fabricación del inhibidor inter-alfa(iaip) a partir de plasma - Google Patents

Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Info

Publication number
CO6680653A2
CO6680653A2 CO13035387A CO13035387A CO6680653A2 CO 6680653 A2 CO6680653 A2 CO 6680653A2 CO 13035387 A CO13035387 A CO 13035387A CO 13035387 A CO13035387 A CO 13035387A CO 6680653 A2 CO6680653 A2 CO 6680653A2
Authority
CO
Colombia
Prior art keywords
lalp
precipitate
fraction
plasma
manufacture
Prior art date
Application number
CO13035387A
Other languages
English (en)
Spanish (es)
Inventor
Shawn F Bairstow
Jennifer Hutsell
Sindhu Ramachandran
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6680653A2 publication Critical patent/CO6680653A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO13035387A 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma CO6680653A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23

Publications (1)

Publication Number Publication Date
CO6680653A2 true CO6680653A2 (es) 2013-05-31

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13035387A CO6680653A2 (es) 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Country Status (14)

Country Link
US (2) US8841248B2 (enExample)
EP (1) EP2596014B1 (enExample)
JP (1) JP5830096B2 (enExample)
KR (1) KR20130093607A (enExample)
CN (1) CN103119058A (enExample)
AU (1) AU2011280907B2 (enExample)
BR (1) BR112013001753A2 (enExample)
CA (1) CA2806645A1 (enExample)
CO (1) CO6680653A2 (enExample)
EA (1) EA201390156A1 (enExample)
ES (1) ES2717177T3 (enExample)
MX (1) MX2013000958A (enExample)
SG (1) SG187599A1 (enExample)
WO (1) WO2012012773A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス, インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之i-iv-1部分沉澱
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2020086879A1 (en) * 2018-10-24 2020-04-30 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN114096558B (zh) * 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
MX2022011950A (es) * 2020-03-31 2022-10-21 Takeda Pharmaceuticals Co Metodo para producir una preparacion de inmunoglobulina a partir de plasma con reduccion del inhibidor de c-1.
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
CN119300842A (zh) * 2022-05-02 2025-01-10 武田药品工业株式会社 通过超滤从血浆制备科恩池浓缩物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
DE59509979D1 (de) * 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
AU2002216968A1 (en) 2000-10-13 2002-04-22 Octapharma Ag Plasma fraction containing bikunin, method for the production thereof and use of the same
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
JP5793076B2 (ja) * 2008-05-28 2015-10-14 プロセラ バイオロジクス, インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Also Published As

Publication number Publication date
US20120053113A1 (en) 2012-03-01
KR20130093607A (ko) 2013-08-22
JP5830096B2 (ja) 2015-12-09
BR112013001753A2 (pt) 2016-05-31
EP2596014B1 (en) 2018-11-28
ES2717177T3 (es) 2019-06-19
AU2011280907B2 (en) 2016-02-04
WO2012012773A1 (en) 2012-01-26
SG187599A1 (en) 2013-03-28
US9505814B2 (en) 2016-11-29
MX2013000958A (es) 2013-11-20
EA201390156A1 (ru) 2014-01-30
US8841248B2 (en) 2014-09-23
EP2596014A1 (en) 2013-05-29
US20150045538A1 (en) 2015-02-12
CA2806645A1 (en) 2012-01-26
AU2011280907A1 (en) 2013-02-07
CN103119058A (zh) 2013-05-22
JP2013535468A (ja) 2013-09-12

Similar Documents

Publication Publication Date Title
PH12014502524B1 (en) Carboxylic acid compounds
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
MX362512B (es) Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
EA201301181A1 (ru) Триазолопиридины
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
MX351467B (es) Nuevos derivados de fosfato de isoquinolinilcarbonilfenil indolizinilo o fosfato de isoquinolinilcarbonilfenil pirrolilo sustituidos, metódo para prepararlos y composiciones farmacéuticas que lo contienen.
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PE20141264A1 (es) Procedimiento de obtencion de una composicion que contiene factores de crecimiento a partir de un compuesto sanguineo, y composicion obtenible por dicho procedimiento
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501342B1 (en) Cosmetic composition containing the slime of snails fed with red ginseng and method for manufacturing same
CL2017001588A1 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
ECSP13012977A (es) Composiciones y métodos para separar, caracterizar y administrar selenoglicoproteínas solubles
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
EA201590564A1 (ru) Стабильные составы

Legal Events

Date Code Title Description
FC Application refused